Axinn is representing McKesson Corporation (NYSE: MCK), a leading, diversified health care services company, in a joint venture combining McKesson’s US Oncology Research (USOR) and HCA Healthcare Inc.'s (NYSE: HCA) Sarah Cannon Research Institute (SCRI). Announced on June 23, 2022, the deal will create a fully integrated oncology research organization aimed at expanding clinical research, accelerating drug development and increasing availability and access to clinical trials for oncology providers and patients, including those in underserved communities. In the transaction with HCA, McKesson will also acquire Genospace, SCRI’s personalized medicine platform and an innovator in precision medicine and clinical trial matching. The Axinn antitrust team is led by partners Daniel Bitton and Jeny Maier, and assisted by associates Carol Liu, Danielle Irvine and Kelly McCluer.